[{"address1": "One Corporate Drive", "address2": "2nd Floor", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "800 466 6059", "website": "https://www.aligos.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-\u00df agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. It also has a clinical collaboration with Xiamen Amoytop Biotech Co., Ltd. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.", "fullTimeEmployees": 68, "companyOfficers": [{"maxAge": 1, "name": "Dr. Lawrence M. Blatt MBA, Ph.D.", "age": 61, "title": "CEO, President & Chairman of the Board", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 1032768, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Julian A. Symons DPHIL", "age": 62, "title": "Executive VP & Chief Scientific Officer", "yearBorn": 1961, "fiscalYear": 2023, "totalPay": 735515, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Lesley Ann Calhoun CPA", "age": 57, "title": "Executive VP & CFO", "yearBorn": 1966, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kristina  Engeseth M.B.A.", "title": "VP and Head of People & Culture", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sushmita M. Chanda DABT, Ph.D.", "age": 56, "title": "Executive Vice President & Chief Development Officer", "yearBorn": 1967, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David B. Smith Ph.D.", "title": "Executive VP & Head of Chemical Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Tse-I  Lin Ph.D.", "title": "VP of Early Compound Development & Belgian Site Head", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Hardean E. Achneck M.D.", "title": "Chief Medical Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 3, "boardRisk": 8, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1733011200, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 33.11, "open": 35.33, "dayLow": 32.0, "dayHigh": 35.45, "regularMarketPreviousClose": 33.11, "regularMarketOpen": 35.33, "regularMarketDayLow": 32.0, "regularMarketDayHigh": 35.45, "beta": 2.116, "forwardPE": -2.6197615, "volume": 316282, "regularMarketVolume": 316282, "averageVolume": 327720, "averageVolume10days": 419630, "averageDailyVolume10Day": 419630, "bid": 33.62, "ask": 34.79, "bidSize": 100, "askSize": 100, "marketCap": 122239408, "fiftyTwoWeekLow": 6.76, "fiftyTwoWeekHigh": 35.45, "priceToSalesTrailing12Months": 20.383427, "fiftyDayAverage": 15.779, "twoHundredDayAverage": 15.9582, "currency": "USD", "enterpriseValue": 56450480, "floatShares": 419891, "sharesOutstanding": 3464200, "sharesShort": 283759, "sharesShortPriorMonth": 121295, "sharesShortPreviousMonthDate": 1730332800, "dateShortInterest": 1732838400, "sharesPercentSharesOut": 0.0791, "heldPercentInsiders": 0.17799, "heldPercentInstitutions": 0.48860002, "shortRatio": 0.5, "shortPercentOfFloat": 0.1263, "impliedSharesOutstanding": 3587890, "bookValue": 15.067, "priceToBook": 2.261233, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -76953000, "trailingEps": -7.25, "forwardEps": -11.92, "lastSplitFactor": "1:25", "lastSplitDate": 1724025600, "enterpriseToRevenue": 9.413, "enterpriseToEbitda": -0.609, "52WeekChange": 1.3255973, "SandP52WeekChange": 0.2764505, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "ALGS", "underlyingSymbol": "ALGS", "shortName": "Aligos Therapeutics, Inc.", "longName": "Aligos Therapeutics, Inc.", "firstTradeDateEpochUtc": 1602855000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "bbc2c389-779c-3f10-ac5a-f071b0904bd5", "messageBoardId": "finmb_581475891", "gmtOffSetMilliseconds": -18000000, "currentPrice": 34.07, "targetHighPrice": 175.0, "targetLowPrice": 60.0, "targetMeanPrice": 103.33333, "targetMedianPrice": 75.0, "recommendationKey": "none", "numberOfAnalystOpinions": 3, "totalCash": 74922000, "totalCashPerShare": 20.882, "ebitda": -92684000, "totalDebt": 9133000, "quickRatio": 3.575, "currentRatio": 3.809, "totalRevenue": 5997000, "debtToEquity": 18.231, "revenuePerShare": 1.005, "returnOnAssets": -0.67323, "returnOnEquity": -1.4669299, "freeCashflow": -49061000, "operatingCashflow": -84998000, "revenueGrowth": -0.608, "operatingMargins": -15.863669, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-12-15"}]